Effect of continuous positive airway pressure combined to nebulization on lung deposition measured by urinary excretion of amikacin

Respiratory Medicine

Volumn 101, Issue 10, 2007, Pages 2051-2055

  Reychler, Gregory ^a   Leal, Teresinha ^a   Roeseler, Jean ^a   Thys, Frédéric ^a   Delvau, Nicolas ^a   Liistro, Giuseppe ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Continuous positive airway pressure; Lung deposition; Nebulizer; Urinary monitoring

Indexed keywords

AMIKACIN;

ADULT; ARTICLE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MONITORING; DRUG URINE LEVEL; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HUMAN EXPERIMENT; LUNG DEPOSIT; LUNG PARENCHYMA; MALE; MEDICAL NEBULIZER; NEBULIZATION; NON INVASIVE MEASUREMENT; NORMAL HUMAN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TISSUE LEVEL;

ADMINISTRATION, INHALATION; ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HUMANS; LUNG; MALE; NEBULIZERS AND VAPORIZERS; SPIROMETRY;

EID: 34548224200     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.06.003     Document Type: Article

References (23)

1. Dolovich M.B., Ahrens R.C., Hess D.R., Anderson P., Dhand R., Rau J.L., et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127 1 (2005) 335-371
2. Finegold S.M. Kanamycin. AMA Arch Intern Med 104 1 (1959) 15-28
3. Clarke J.T., Libke R.D., Regamey C., and Kirby W.M. Comparative pharmacokinetics of amikacin and kanamycin. Clin Pharmacol Ther 15 6 (1974) 610-616
4. Dequin P.F., Faurisson F., Lemarie E., Delatour F., Marchand S., Valat C., et al. Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur Respir J 18 2 (2001) 316-322
5. Ilowite J.S., Gorvoy J.D., and Smaldone G.C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 136 6 (1987) 1445-1449
6. Palmer L.B., Smaldone G.C., Simon S.R., O'Riordan T.G., and Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 26 1 (1998) 31-39
7. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 26 2 (2005) 319-338
8. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests. European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
9. Coates A.L., Allen P.D., MacNeish C.F., Ho S.L., and Lands L.C. Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest 119 4 (2001) 1123-1130
10. Kesten S., and Rebuck A.S. Ventilatory effects of nasal continuous positive airway pressure. Eur Respir J 3 5 (1990) 498-501
11. Hakkinen A.M., Uusi-Heikkila H., Jarvinen M., Saali K., and Karhumaki L. The effect of breathing frequency on deposition of drug aerosol using an inhalation-synchronized dosimeter in healthy adults. Clin Physiol 19 3 (1999) 269-274
12. Neale M.G., Brown K., Hodder R.W., and Auty R.M. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmacol 22 4 (1986) 373-382
13. O'Callaghan C., and Barry P.W. The science of nebulised drug delivery. Thorax 52 Suppl 2 (1997) S31-S44
14. Parkes S.N., and Bersten A.D. Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask. Thorax 52 2 (1997) 171-175
15. Dolovich M.B., Killian D., Wolff R.K., Obminski G., and Newhouse M.T. Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. Am Rev Respir Dis 115 3 (1977) 397-402
16. Reychler G., Keyeux A., Cremers C., Veriter C., Rodenstein D.O., and Liistro G. Comparison of lung deposition in two types of nebulization: intrapulmonary percussive ventilation versus jet nebulization. Chest 125 2 (2004) 502-508
17. Reychler G., Wallemacq P., Rodenstein D.O., Cumps J., Leal T., and Liistro G. Comparison of lung deposition of amikacin by intrapulmonary percussive ventilation and jet nebulization by urinary monitoring. J Aerosol Med 19 2 (2006) 199-207
18. Franca E.E., Dornelas de Andrade A.F., Cabral G., Almeida F.P., Silva K.C., Galindo F.V., et al. Nebulization associated with bi-level noninvasive ventilation: analysis of pulmonary radioaerosol deposition. Respir Med 100 4 (2006) 721-728
19. Laube B.L., Geller D.E., Lin T.C., Dalby R.N., Diener-West M., and Zeitlin P.L. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respir Care 50 11 (2005) 1438-1444
20. Melchor R., Biddiscombe M.F., Mak V.H., Short M.D., and Spiro S.G. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48 5 (1993) 506-511
21. Matthay M.A. Function of the alveolar epithelial barrier under pathologic conditions. Chest 105 3 Suppl (1994) 67S-74S
22. Cooney G.F., Lum B.L., Tomaselli M., and Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 34 3 (1994) 255-259
23. Oeltgen P.R., Shank Jr. W.A., Blouin R.A., and Clark T. Clinical evaluation of the Abbott TDx fluorescence polarization immunoassay analyzer. Ther Drug Monit 6 3 (1984) 360-367